Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine

Agaath Hedina Manickam; Alina Buture; Esther Tomkins; Martin Ruttledge

doi:10.1002/ccr3.4625

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine

Clin Case Rep. 2021 Aug 16;9(8):e04625. doi: 10.1002/ccr3.4625. eCollection 2021 Aug.

Authors

Agaath Hedina Manickam¹, Alina Buture², Esther Tomkins³, Martin Ruttledge³

Affiliations

¹ Department of Human Genetics and Molecular Biology Bharathiar University Coimbatore India.
² Mater Misericordiae University Hospital Dublin Ireland.
³ Beaumont Hospital Dublin Ireland.

Abstract

Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.

Keywords: CGRP monoclonal antibodies; Raynaud's phenomenon; chronic migraine; erenumab.

Publication types

Case Reports